Understanding Ozempic Gastroparesis: What You Need to Know

Latest update (2026-01)

FDA enforcement record (Ongoing): Presence of Particulate Matter: Hair was found in a prefilled syringe. [source]

From General Health Information to Targeted Risk Assessment

If you or a loved one has experienced persistent nausea, vomiting, or abdominal pain after taking Ozempic, you may be concerned about gastroparesis. This condition, where the stomach empties slowly, has been linked to GLP-1 medications. Building on decades of medical research into drug safety, this page explains what gastroparesis is, how it relates to Ozempic, and what steps you can take to address your health concerns.

Bridging General Health Context to Ozempic-Specific Concerns

Building on the foundation of general health education, we now focus specifically on Ozempic (semaglutide), a glucagon-like peptide-1 (GLP-1) receptor agonist approved for glycemic control in type 2 diabetes. Its mechanism involves slowing gastric emptying, which can lead to gastrointestinal adverse effects. Among these, gastroparesis—a condition characterized by delayed gastric emptying without mechanical obstruction—has been reported in association with Ozempic use. This section examines the clinical presentation and diagnosis of gastroparesis, Ozempic's pharmacology and reported adverse effects, mechanistic pathways linking the drug to gastroparesis, adequacy of warnings, settlement-related considerations for affected patients, and the timeline between exposure and documented harm.

Clinical Evidence Linking Ozempic to Gastroparesis

Gastroparesis presents with symptoms such as nausea, vomiting, early satiety, postprandial fullness, bloating, and abdominal pain. Diagnosis typically involves gastric emptying scintigraphy, which measures the rate of gastric emptying after a radiolabeled meal. The condition can be idiopathic or secondary to diabetes, surgery, or medications. In the context of Ozempic, the drug's pharmacological action of delaying gastric emptying is intended to improve glycemic control but can exacerbate or induce gastroparesis-like symptoms. Clinical trials have documented gastrointestinal adverse reactions at higher rates in Ozempic-treated patients compared to placebo. In placebo-controlled trials, gastrointestinal adverse reactions occurred more frequently among patients receiving Ozempic than placebo (placebo 15.3%, Ozempic 0.5 mg 32.7%, Ozempic 1 mg 36.4%) (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). The majority of reports of nausea, vomiting, and/or diarrhea occurred during dose escalation. More patients receiving Ozempic 0.5 mg (3.1%) and Ozempic 1 mg (3.8%) discontinued treatment due to gastrointestinal adverse reactions than patients receiving placebo (0.4%) (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). In a trial with Ozempic 1 mg and 2 mg, gastrointestinal adverse reactions occurred more frequently among patients receiving Ozempic 2 mg (34.0%) vs Ozempic 1 mg (30.8%) (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). Additional gastrointestinal adverse reactions with a frequency of less than 5% included dyspepsia (placebo 1.9%, 0.5 mg 3.5%, 1 mg 2.7%), eructation (0%, 2.7%, 1.1%), flatulence (0.8%, 0.4%, 1.5%), gastroesophageal reflux disease (0%, 1.9%, 1.5%), and gastritis (0.8%, 0.8%, 0.4%) (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). These data indicate a dose-dependent increase in gastrointestinal adverse events, which may include gastroparesis.

Mechanistic Pathways and Warning Adequacy

Mechanistically, GLP-1 receptor agonists like Ozempic slow gastric emptying by inhibiting vagal nerve activity and reducing antral contractions. This effect is mediated through GLP-1 receptors in the gastrointestinal tract and central nervous system. Chronic use may lead to sustained delay in gastric emptying, potentially causing or unmasking gastroparesis in susceptible individuals. The drug's labeling acknowledges gastrointestinal adverse reactions but does not specifically list gastroparesis as a warning. The warnings section includes hypersensitivity reactions such as anaphylaxis and angioedema (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166), but does not address the risk of gastroparesis. This omission raises questions about the adequacy of warnings for patients who develop severe gastric symptoms.

Statute of Limitations and Settlement Considerations in California

For patients in California considering legal action related to Ozempic-associated gastroparesis, the statute of limitations is a critical factor. In California, personal injury claims generally must be filed within two years from the date of injury or discovery of the injury. For product liability cases, the statute may begin when the plaintiff knew or should have known that the injury was caused by the product. Given the timeline between Ozempic exposure and documented harm, patients who experienced gastroparesis symptoms during or after treatment should document the onset of symptoms, diagnosis, and any medical records linking the condition to Ozempic. Settlement considerations for affected patients may include compensation for medical expenses, lost wages, pain and suffering, and ongoing care. The adequacy of warnings is a key element in such claims, as manufacturers have a duty to provide reasonable warnings about known risks. The absence of a specific gastroparesis warning in Ozempic's labeling may support arguments that the manufacturer failed to adequately inform patients and healthcare providers.

Important Notice

This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.

Frequently Asked Questions

What is the statute of limitations for Ozempic gastroparesis claims in California?

In California, personal injury claims generally must be filed within two years from the date of injury or discovery of the injury. For product liability cases, the statute may begin when the plaintiff knew or should have known that the injury was caused by the product. It is crucial to consult an attorney promptly to ensure your claim is filed within the applicable time frame.

Does Ozempic's labeling warn about gastroparesis?

Ozempic's labeling acknowledges gastrointestinal adverse reactions but does not specifically list gastroparesis as a warning. The warnings section includes hypersensitivity reactions such as anaphylaxis and angioedema (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166), but does not address the risk of gastroparesis. This omission may be relevant in legal claims regarding failure to warn.

Does submitting information create an attorney-client relationship?

No. Submission requests an initial records screening only and does not create an attorney-client relationship.

Information Registry: individuals with documented Ozempic exposure and a confirmed Gastroparesis diagnosis may request an independent eligibility review. [Begin Assessment]

References

DailyMed - Ozempic Labeling

Request a Free Case Review

This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.